Biochemical and biophysical research communications · 2026
Identification of novel diimide and hydrazone scaffolds for synergistic HIV-1 shock and kill strategies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sukegawa Sayaka, Matsuda Kouki, Kitamura Haruki, Tanimoto Kousuke, Fujisaki Chieko, Kobayakawa Takuya, Tsukitani Tomoya, Yoshino Hiroki, Tamamura Hirokazu, Maeda Kenji, Takeuchi Hiroaki
Аннотация
Combination antiretroviral therapy (ART) is currently the standard-of-care to control HIV replication in infected individuals. However, since this treatment mainly targets viral enzymes, the presence of latently-infected reservoirs and the emergence of drug resistance remain major barriers to viral eradication. To overcome this, a "Shock and Kill" approach has been developed, using "latency-reversing agents" (LRAs) to activate latent proviruses ("shock"), leading to viral elimination by ART and immune-mediated clearance ("kill"). We previously screened a small-molecule library on monocytic and CD4+ T cell lines latently infected with HIV, and identified two novel LRA candidates (compounds #C1 and #C3). Based on their structural features, we now identified two related derivatives, compounds #C2 and #C4. Compounds #C1 and #C2 possess diimide structures, whereas #C3 and #C4 have hydrazone structures. All four compounds synergistically enhanced LRA activity when combined with JQ1 or PKC activators in J-Lat 10.6 cells. Notably, combining #C4 with JQ1 further enhanced HIV reactivation showing limited responsiveness to JQ1 alone in J-Lat 10.6 model cells. In ex vivo purified CD4+ T cells from ART-suppressed individuals, #C4 elicited a statistically significant, donor-matched increase in HIV-1 transcription (ratio paired t-test, P = 0.0137, n = 8), whereas JQ1 did not reach significance under the same paired analysis despite a comparable mean magnitude. Notably, #C4 additionally induced measurable reactivation in donors with limited responsiveness to JQ1 alone. RNA-sequencing analyses indicated that compound #C4, JQ1 and PKC activators mediated LRA activity through distinct molecular mechanisms. Collectively, these findings delineate a structurally novel class of LRA candidates that engage a latency-reversal mechanism distinct from that of JQ1 and canonical PKC signaling, and thereby support further investigation of their utility within combinatorial strategies aimed at HIV-1 reservoirs.